BioSpace News Archive

Amneal Pharmaceuticals, Inc. announced that a delegation of senior members of the U.S. Department of Health and Human Services and U.S. Food and Drug Administration together with local government officials recently visited the Company’s manufacturing facility in Matoda, India.

FibroGen, Inc. (NASDAQ: FGEN) today announced topline data from the Phase 3 LELANTOS-2 trial of pamrevlumab for the treatment of ambulatory patients with Duchenne muscular dystrophy (DMD) on background systemic corticosteroids.

Tango Therapeutics, Inc., a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, announced changes to its Board of Directors.

10x Genomics, Inc., a leader in single cell and spatial biology, announced that it has shipped more than 100 Xenium Analyzer instruments in the eight months since the platform’s launch.

AIDS Healthcare Foundation commended President Joseph Biden on his administration’s efforts to control drug pricing by compelling pharmaceutical companies choosing to participate in Medicare to engage in drug price negotiations.

Shanghai Fosun Pharmaceutical Co., Ltd.* announced its 2023 Interim Results for the first half of 2023.

Mindray, a global leader in providing advanced medical device solutions, has unveiled upgrades to its A7 and A5 anaesthesia systems under the A Series Anaesthesia.

Evolus, Inc., a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, announced that members of its management team will be participating in two investment conferences in September.

Amsterdam, Netherlands and Calgary, Alberta--(Newsfile Corp. - August 29, 2023) - Resverlogix Corp. (TSX: RVX) (“Resverlogix”) (TSX:RVX) today announced that new guidelines published by the European Society of Cardiology

NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS) today highlighted A Prospective Study on the Effect of Auricular Percutaneous Electrical Nerve Field Stimulation (PENFS™) in Patients with Post-Concussion Syndrome (PCS), a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of IB-Stim™ in children with post-concussion symptoms.